EUPROMS study
EUROPA UOMO patient reported outcome study
The first ever survey in PCa from patients for patients

André Deschamps Ing. MBA
Chairman
Disclosures

- Sponsored by 3 pharmaceutical companies.
- They have had no role or influence in any aspect of the study and this will remain the position.
EUPROMS study

Methodology and sample profiles
Methodology

20 minute online survey with patients with prostate cancer who have received treatment

Objective
- Examine the quality of life of PCa patients Europe wide
- Use of validated quality of life questionnaires
  - EPIC 26
  - EORTC
  - EQ-5D-5L

Recruitment and data collection
- Via a link placed on the Europa Uomo website
- Actively circulated by members of Europa Uomo
- Data collected by Cellohealth UK

Patient screening criteria
- Male with prostate cancer
- Receiving or have received some treatment for their prostate cancer, including active surveillance
- Not affiliated in any way with a pharmaceutical company
- Not participated in related research in the past month

Languages
- Questionnaire available in 19 languages
### Geographic coverage and valid answers

#### 24 countries

- Austria: 66
- Belgium: 339
- Bulgaria: 1
- Czech Republic: 3
- Denmark: 188
- Estonia: 8
- Finland: 65
- France: 234
- Germany: 253
- Greece: 1
- Hungary: 10
- Ireland: 26
- Italy: 71
- Latvia: 11
- Lithuania: 52
- Norway: 506
- Poland: 109
- Portugal: 75
- Slovak Republic: 8
- Spain: 55
- Sweden: 386
- Switzerland: 7
- The Netherlands: 244
- UK: 187
- Other (mainly Cyprus): 38

#### 2,4 Million (estimated) have answered the questionnaire

#### 1,22 per 1000 patients per 1000 patients

- 5 years prevalence: 1,3 million*
- 10 years prevalence: 2,4 million**

*Source centre for parliamentary studies eu

**Calculated based on known figures for some countries
Respondence profile:

**Current age**
- Mean: 70 years
- Distribution:
  - <55: 4%
  - 55-59: 6%
  - 60-64: 13%
  - 65-69: 21%
  - 70-74: 26%
  - 75-79: 19%
  - 80+: 10%

**Age at Diagnosis**
- Mean: 64 years
- Distribution:
  - <55: 11%
  - 55-59: 17%
  - 60-64: 24%
  - 65-69: 24%
  - 70-74: 16%
  - 75-79: 6%
  - 80+: 2%

**Living situation**
- With spouse: 82%
- Alone: 14%
- With other family: 3%

**Employment**
- Higher managerial: 20%
- Intermediate: 34%
- Junior managerial: 15%
- Skilled manual worker: 12%
- Semi-skilled manual: 2%
- Unskilled manual: 1%
- Unemployed: 1%
- Other: 14%

**Education**
- University entrance certificate: 31%
- Entrance certificate for a higher technical college: 28%
- Comprehensive school: 13%
- Intermediate secondary school: 11%
- Lower secondary school or equivalent: 7%
- Other: 8%
- None: 1%
Treatments profile

Amount of treatments

Treatment = 1

Treatment = 2
EUPROMS study

EORTC,EQ-5D-5L and EPIC first results
EORTC functional score

High score is positive

- Previously but not currently on treatment
- Currently on active treatment
- 2nd or later treatment

Physical functioning  Role functioning  Cognitive functioning  Emotional functioning  Social functioning  Global Health Status
EORTC symptom score

Low score is positive

Previously but not currently on treatment
Currently on active treatment
2nd or later treatment

2nd treatment and cancer recurrence = worse scores overall
Mental health is impacted: 45% reporting at least some anxiety/depression.
Sexual function is the most impacted area

<table>
<thead>
<tr>
<th>Condition</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urinary incontinence</td>
<td>72</td>
</tr>
<tr>
<td>Urinary obstructive</td>
<td>83</td>
</tr>
<tr>
<td>Bowel</td>
<td>88</td>
</tr>
<tr>
<td>Sexual</td>
<td>28</td>
</tr>
<tr>
<td>Hormonal</td>
<td>74</td>
</tr>
</tbody>
</table>
This 28 sexual score is much lower than other studies.
50% report that sexual function is a moderate or big problem

- Big problem: 28%
- Moderate problem: 17%
- Small problem: 15%
- Very small problem: 18%
Only 34% have used medication or devices
EPIC sexual function: satisfaction with medication or devices

- **Viagra or other pill**
  - 19% Have not tried it
  - 40% Tried it but was not helpful
  - 9% It helped but I am not using it now
  - 18% It helped and I use it sometimes
  - 13% It helped and I always use it

- **Penile injection therapy**
  - 67% Have not tried it
  - 11% Tried it but was not helpful
  - 10% It helped but I am not using it now
  - 7% It helped and I use it sometimes
  - 6% It helped and I always use it

- **Vacuum erection device**
  - 63% Have not tried it
  - 14% Tried it but was not helpful
  - 8% It helped but I am not using it now
  - 9% It helped and I use it sometimes
  - 5% It helped and I always use it

- **Muse (intra-urethral alprostadil suppository)**
  - 83% Have not tried it
  - 11% Tried it but was not helpful
  - 3% It helped but I am not using it now
  - 2% It helped and I use it sometimes

- **Other**
  - 85% Have not tried it
  - 6% Tried it but was not helpful
  - 2% It helped but I am not using it now
  - 3% It helped and I use it sometimes
  - 7% It helped and I always use it
Key messages so far

- The collected data are representative for the patient population.
- Sexual function is the major effect of all PCA treatments. The measured score is much lower than expected.
- Fatigue, insomnia and anxiety/depression are other important effects.
- Patients who are receiving their 2nd or later treatment due to cancer recurrence have worse scores across all metrics.
Next steps

- **Analyse** results further
  Partner Prof. Monique Roobol, Erasmus University Medical center, Department of Urology, Rotterdam, NL

- **Publish** results and awareness campaign

- **Update** EAU in Amsterdam
Next steps budget

- **Analyse** results further  15 000 €
- **Publish** results at booth EAU 10 000 €